Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + IBI305 ± chemotherapy vs pemetrexed + cisplatin in EGFR-mutant non-squamous NSCLC after TKI failure
CTR20182550Phase 3Suspended
- Sponsor
- Innovent Biologics
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab, bevacizumab in Non-small cell lung cancer (NS-NSCLC), sponsored by Innovent Biologics. Started Jan 2019; status: suspended.
02
Drugs
sintilimabbevacizumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20182550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182550.